Share this article

Vurolenatide is a recombinant peptide commercialized by 9 Meters Biopharma, with a leading Phase III program in Short Bowel Syndrome. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vurolenatide’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Vurolenatide is expected to reach an annual total of $160 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Vurolenatide Overview

NB-1001 (XTEN-GLP1) is under development for the treatment of short bowl syndrome. NB-1001 is a proprietary long-acting version of exenatide. NB-1001 is administered through subcutaneous route as a replacement therapy. The drug candidate acts by targeting GLP-1 receptor. The drug candidate is developed based on the XTEN platform technology. NB-1001 was also under development for type II diabetes.

9 Meters Biopharma Overview

9 Meters Biopharma, formerly Innovate Biopharmaceuticals Inc, is a clinical-stage biopharmaceutical company developing novel medicines for autoimmune and inflammatory diseases. The company’s pipeline products include Larazotide, an orally administered, gut-restricted tight-junction regulator for celiac disease, NM-003, a long-acting GLP-2 analog, under orphan indication selection, NM-136 and NM-004. 9 Meters Biopharma is headquartered in Raleigh, North Carolina, the US.

The operating loss of the company was US$42 million in FY2022, compared to an operating loss of US$36.8 million in FY2021. The net loss of the company was US$43.8 million in FY2022, compared to a net loss of US$36.8 million in FY2021.

For a complete picture of Vurolenatide’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 3 November 2013

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.